Lucid Diligence Brief: Galderma resubmits RelabotulinumtoxinA to the FDA
Lucid Diligence Brief: Galderma resubmits RelabotulinumtoxinA to the FDA…
Lucid Diligence Brief: Kyowa Kirin regains rocatinlimab rights from Amgen
Lucid Diligence Brief: Kyowa Kirin regains rocatinlimab rights from Amgen…
Lucid Diligence Brief: Ultragenyx UX111 BLA resubmission
Lucid Diligence Brief: Ultragenyx UX111 BLA resubmission Professional audiences…
Lucid Diligence Brief: Formation Bio licenses miR-124 activator FHND5032 from CTFH
Lucid Diligence Brief: Formation Bio licenses miR-124 activator FHND5032 from…
Lucid Diligence Brief: Seamless Therapeutics and Lilly enter gene-writing pact in hearing loss
Lucid Diligence Brief: Seamless Therapeutics and Lilly enter gene-writing pact…
Lucid Diligence Brief: Boehringer Ingelheim and Simcere partner in IBD
Lucid Diligence Brief: Boehringer Ingelheim and Simcere partner in IBD…
Lucid Diligence Brief: Fortitude Biomedicines launch with $13M seed
Lucid Diligence Brief: Fortitude Biomedicines launch with $13M seed…
Lucid Diligence Brief: PAQ Therapeutics Series B for PT0511 pan-KRAS degrader
Lucid Diligence Brief: PAQ Therapeutics Series B for PT0511 pan-KRAS degrader…
Lucid Diligence Brief: CORXEL $287m Series D1 for oral GLP-1 development
Lucid Diligence Brief: CORXEL $287m Series D1 for oral GLP-1 development…
Lucid Diligence Brief: Mendra $82 million Series A to support AI-enabled rare-disease therapeutics
Lucid Diligence Brief: Mendra $82 million Series A to support AI-enabled…
Lucid Diligence Brief: Janux Therapeutics and Bristol Myers Squibb collaboration
Lucid Diligence Brief: Janux Therapeutics and Bristol Myers Squibb…
Lucid Diligence Brief: GSK to acquire RAPT Therapeutics
Lucid Diligence Brief: GSK to acquire RAPT Therapeutics Professional audiences…